Phase II neoadjuvant study (neoMONARCH) comparing the biological effects of abemaciclib plus anastrozole vs abemaciclib monotherapy vs anastrozole monotherapy in women with early-stage HR+, HER2− BC. This evidence concerns the gene ERBB2 and breast cancer.